Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of probable Alzheimer Disease (AD), with Mini Mental State Examination (MMSE) score of 16-26, and brain magnetic resonance imaging (MRI) consistent with the diagnosis of AD~* Concurrent use of cholinesterase inhibitor or memantine allowed, if stable~* Caregiver will participate and be able to attend clinic visits with patient~Exclusion Criteria:~* Significant neurological disease other than AD~* Major psychiatric disorder~* Contraindication to undergo brain MRI \[e.g., pacemaker, cerebrospinal fluid (CSF) shunt, or foreign metal objects in the body\]~* Women of childbearing potential

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Bapineuzumab 0.5 mg/kg (Type: EXPERIMENTAL): None
- Bapineuzumab 1.0 mg/kg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).